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E-mail address: m.ﬁdani@unirelab.it (M. Fidani).The possibility of an endogenous presence of the glucocorticoid prednisolone has already been demon-
strated in bovine and horse urine, with the aim of clarifying its origin in this matrix, which is used by
ofﬁcial agencies for the control of illicit treatments. From this point of view, the endogenous nature of
prednisolone could be a major topic in doping control of both amateur and professional human athletes.
A study was therefore made on 34 human volunteers (13 males and 21 females; aged 22–62) to detect
the presence of prednisolone in their urine by HPLC–MS3. One of the volunteers underwent vernal allergy
treatment with betamethasone for two subsequent years. An investigation was carried out with the aim
of verifying if the suppression, and the circadian rhythm, of cortisol urinary levels could also apply to
prednisolone. The results of the study show that prednisolone was present in the urine of all 34 volun-
teers, with a concentration very close to 100-times lower that of cortisol, with no dependence on gender.
The same ratio (1/100) was observed in the prednisolone and cortisol levels detected during the 24 h
together with the suppression of prednisolone by betamethasone treatment.
These data demonstrate the endogenous nature of low concentrations of prednisolone in human urine,
and motivate further studies about the biosynthetic pathways of this corticosteroid and its relationship
with stress in humans, as already described in cows.
 2012 Elsevier Inc. All rights reserved.1. Introduction
Prednisolone (11b,17a,21-trihydroxy-pregna-1,4-diene-3,20-
dione) is a glucocorticosteroid with a similar structure to cortisol
(11b,17a,21-trihydroxy-pregn-4-ene-3,20-dione), differing from
this hormone by only one double bond at the C1–C2 position on
ring A (Fig. 1). Prednisolone was ﬁrst synthesised in 1955, through
microbiological oxidation of cortisol [1]. Together with its prodrug
prednisone, prednisolone is used both in human and veterinary
medicine because of its anti-inﬂammatory and immunosuppres-
sive activities [2,3]. The illicit use of prednisolone by athletes is
monitored by the World Anti-Doping Agency (WADA), using in-
competition controls for all corticosteroids administered by sys-
temic (e.g. oral), non-systemic and non-topical (e.g. intra-articular,
inhalation) routes [4] are performed. The Fédération Equestre
Internationale (FEI™) considers prednisolone as a ‘‘controlled med-
ication substance’’ [5], i.e. a substance that must not be ‘‘present in
the horse’s body during an event’’ [6]. In the ﬁeld of animal hus-
bandry, prednisolone use is permitted in the European Union, withll rights reserved.
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: +39 0233514200.the restriction to meet the maximum residue limits (MRLs) in edi-
ble tissues [7]; its presence in the urine of food-producing animals
is not, however, provided.
Some studies show that a problem in ﬁnding of prednisolone in
human, equine and bovine urine exists: this corticosteroid could in
fact be the product of a microbiological dehydrogenation of cortisol
after the collection of urine samples [8–11], and endogenous meta-
bolic pathways could also be involved in bovine [12] and equine [13]
animals. The analogies between the anabolic steroid boldenone
(17b-hydroxy-1,4-androstadiene-3-one) and the glucocorticoster-
oid prednisolone have to be underlined: both steroids have a C1–
C2 double bond; cortisol is released by the adrenal gland in response
to stimulation by adrenocorticotropic hormone (ACTH); also andro-
stenedione (4-androsten-3,17-dione; AED), the direct precursor of
testosterone (17b-hydroxy-4-androsten-3-one) can be released by
adrenals in response to the same stimulation [14]; and AED differs
from the precursor of boldenone, androstadienedione (1,4-andro-
stadiene-3,17-dione; ADD), in the same way that cortisol differs
from prednisolone, i.e. the dehydrogenation of the carbon atoms in
position 1 and 2. In a study carried out using GC/C/IRMS (gas chro-
matography/combustion/isotope ratio mass spectrometry), Piper
et al. [15] showed that the 13C/12C isotope ratios of boldenone and
its main metabolite 5b-androst-1-en-17b-ol-3-one were inconsis-
tent with an exogenous origin in 11 out of 23 athlete urine samples
Fig. 1. Chemical structures of cortisol, prednisolone and betamethasone.
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lected from the same athlete within a one-month interval, the
authors strongly afﬁrmed the endogenous production of boldenone,
likely in the gut, working as an ‘‘endocrine active side organ’’.
In the present work, it was hypothesised that prednisolone syn-
thesis could be endogenous, similar to boldenone synthesis. The
presence of the glucocorticosteroid in urine was therefore investi-
gated in 34 healthy volunteers of both sexes in order to understand
if the frequency of prednisolone detection and the correlation with
cortisol urinary levels conﬁrmed this supposition. The predniso-
lone urinary levels of a male volunteer, orally treated to prevent
pollen allergy with betamethasone (9a-ﬂuoro-11b,17a,21-trihy-
droxy-16b-methylpregna-1,4-diene-3,20-dione) on medical pre-
scription, were also investigated, in two different years, before,
during and after the treatment.2. Experimental
2.1. Reagents and chemicals
Cortisol, prednisolone, betamethasone and methylprednisolone
(as internal standard) were from Sigma–Aldrich (St. Louis, MO,
USA); tert-butyl methyl ether was from Panreac (Barcelona, Spain);
acetonitrile, methanol and formic acid were from J.T. Baker
(Deventer, Holland). All solvents used were of HPLC grade. Water
was freshly prepared with a Milli-Q Advantage A10 Ultrapure
Water Puriﬁcation System (Merck-Millipore, Darmstadt, Ger-
many). Standard stock solutions (1 mg/mL) were prepared by dis-
solving the dry powder of each analyte in methanol; solutions
were stored at 20 C. Working solutions were prepared daily by
diluting the stock solutions with methanol.
Bentelan (effervescent tablets 0.5 or 1 mg–betamethasone 21-
disodium phosphate 0.6578 or 1.316 mg equal to betamethasone
0.5 or 1 mg, respectively) was from Deﬁante Farmacêutica, S.A.,
Funchal, Portugal.2.2. Study population
In total, 34 healthy individuals (33 did not use glucocorticoids,
one was studied for two subsequent years both before, during and
after a treatment with a glucocorticoid) participated in this study.
The urine samples from the volunteers (13 males aged 30–61; 21
females aged 22–62) were analysed. All individuals provided one
urine sample, except for two male and three female individuals
who gave two samples, collected within a six-month interval.
One individual, a 41-year old male, gave urine samples nine times
in a 24-h period before, and once a day (at 10.00 A.M.) during an
oral treatment with betamethasone (a medical prescription to pre-
vent pollen allergy) and 12 and 15 h after the last intake of the cor-
ticosteroid; in a second trial in the subsequent year, urine was
collected from the same subject 1 h before the ﬁrst administration,
at the moment (11:00 P.M.) and 7 h (6:00 A.M.) after each oral
administration of betamethasone and over 3.5 days after the last
administration at different intervals by urinary urges. The dosages
were: one 0.5-mg tablet orally administered per day for 11 days at10.00 A.M. (ﬁrst trial) or one 1-mg tablet orally administered per
day for 7 days at 11.00 P.M. (second trial).
All samples were analysed for the presence of prednisolone and
cortisol; in the second trial concerning the betamethasone treat-
ment, this corticosteroid was considered for analysis, too. All par-
ticipants gave written informed consent.
2.3. Sample collection
All samples were collected in sterile urine containers. The ones
from non-treated volunteers were immediately extracted and ana-
lysed, while the ones from the betamethasone-treated individual
were placed in a freezer at 18 C, transferred to the laboratory,
thawed and processed, avoiding any further storage.
2.4. Sample preparation
Urine samples (5 mL) were spiked with the internal standard
methylprednisolone to give a ﬁnal concentration of 10 ng/mL.
Tert-butyl methyl ether (5 mL) was added. After shaking in a verti-
cal rotary shaker for 30 min, the sample was centrifuged at 3000g
for 30 min. The upper organic layer was collected with a Pasteur
pipette, transferred to a 10-mL glass tube and dried under vacuum
in a centrifugal evaporator at a temperature of 45 C. The residue
was dissolved in 100 lL of the mobile phase (30% acetonitrile,
70% formic acid in a 0.1% aqueous solution) and transferred to vials
for HPLC–MS3 full-scan analysis. The injection volume was 5 lL.
2.5. Sample analysis
The HPLC–MS3 analysis (and the problems involved) was de-
scribed in detail in a previous work [13]. Brieﬂy, an LTQ linear
ion trap mass spectrometer equipped with an ESI source (Thermo
Fisher Scientiﬁc, San José, CA, USA), connected to a Surveyor Auto-
sampler and an MS Pump (Thermo Fisher Scientiﬁc, San José, CA,
USA), was used. The chromatographic separation was performed
at ambient temperature, in the isocratic condition, on a reversed-
phase Sunﬁre column (150  2.1 mm, 3.5 lm; Waters, Milford,
MA, USA) equipped with a Sunﬁre C18 Guard Column
(2.1  10 mm i.d., 3.5 lm). The mobile phase consisted of a mix-
ture of 70% water with 0.1% formic acid and 30% acetonitrile at a
ﬂow rate of 0.3 mL/min. Methylprednisolone (10 ng/mL) was used
as the internal standard. The linear ion trap mass spectrometer was
operated in negative electrospray ionisation mode (ESI-) under the
following conditions: sheath and auxiliary gas (nitrogen) ﬂow rates
of 40 and 20 arbitrary units, respectively; spray voltage of 4 kV; ion
transfer capillary temperature of 275 C; capillary voltage of 6 V;
tube lens offset of 50 V. Helium was used for collision-induced
dissociation.
Prednisolone showed, in full scan MS, the very abundant and
stable formate adduct 405 ([M + HCOO]). Consequently, this ion
was used as precursor ion for the MS2 analysis. The most abundant
ion detected after the collision hadm/z = 329, which was then used
as a precursor for MS3 fragmentation. The analysis was performed
in full-scan mode (Table 1). The ESI–MS parameters had been
Table 1
Major ions for prednisolone, cortisol and the internal standard methylprednisolone detected by LC–MS3 full scan (C.E.: collision energy). Ions for quantiﬁcation indicated in bold.
Compound MS2 MS3
([M+HCOO]) precursor ion (m/z) C.E. (%) Precursor ion (m/z) C.E. (%) Product ions (m/z)
Prednisolone 405 15 329 18.5 313 295 280 187
Cortisol 407 20 331 23 297
Methylprednisolone 419 20 343 20 309
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lone (1 lg/mL) at a ﬂow rate of 20 lL/min. Data acquisition and
analysis were accomplished using Xcalibur software version 1.4
(Thermo Fisher Scientiﬁc).
2.6. Method validation
Blank urine belonged to the subjects participating in the study.
Betamethasone-free urine was easily found. As regards predniso-
lone and cortisol, blank urine came from the individual treated
with betamethasone, from seventh day to the end of treatment.
The absence of the studied corticosteroids was checked by the ana-
lytical method described above.
A calibrationcurvewas thuspreparedwithblankurineandwater
samples, spiked to give known concentrations of betamethasone or
prednisolone and cortisol, (10, 50, 100, 500 pg/mL, 1, 10, 100 and
200 ng/mL). Three replicatesweremeasured on three different days
after liquid–liquid extraction. The following parameterswere calcu-
lated: precision, expressed as intra- and inter-day coefﬁcient of vari-
ations (CV%), on four blank urine samples, spiked with 100 pg/mL,
corresponding to twice the limit of quantiﬁcation (LOQ); recovery
(%), based on three samples spiked at six different concentrations
(10, 50, 100, 500 pg/mL, 1 and 10 ng/mL) in water and urine, calcu-
lated as (Observed value–Baseline value)/spike amount; limit of
detection (LOD), deﬁned as the lowest level at which a compound
could be identiﬁed (signal-to-noise ratio greater than 3) and LOQ,
deﬁned as the lowest level at which a compound could be identiﬁed
and quantiﬁed (signal-to-noise ratio greater than 10); between-run
accuracy, on three different days using four different samples spiked
with 100 pg/mL (twice the LOQ).
2.7. Statistical analysis
The Kolmogorov and Smirnov method was used to test the
assumption of a Gaussian distribution. Unpaired t-test was used
when the assumption was conﬁrmed to compare males and fe-
males, otherwise a non-parametric Mann–Whitney test was used.
The correlation between cortisol and prednisolone urinary concen-
trations was checked through the non-parametric, Spearman Rank
Correlation test except in the 24-h period before treatment of the
ﬁrst trial on the treated individual where the Pearson correlation
was used, due to the Gaussian distribution of the values. Because
of the similarity of the results, no statistical tests were performed
in the second trial. The software used was GraphPad InStat™ ver-
sion 3.00 (GraphPad Software, San Diego, California USA;
www.graphpad.com).
3. Results
3.1. Identiﬁcation of prednisolone
In a previous study in our laboratories on prednisolone presence
in equine urine, [13] we referred to the difﬁculties found by some
Authors in detecting prednisolone. The analysis of urine samples
was therefore carried out following the experience made on that
matrix. After preliminary trials (data not shown) that conﬁrmedthe conclusions already drawn, the full-scan LC MS3 with a linear
ion trap was so chosen.
3.2. Method validation
The correlation coefﬁcient was 0.99 for each corticosteroid. The
intra-day CVs% ranged between 6.8 and 8.2, the inter-day CVs%
ranged between 7.8 and 11.2 for all corticosteroids. The recoveries
ranged from 89% to 94% in urine and water, indicating the absence
of a matrix effect. The LOD was 10 pg/mL and the LOQ was 50 pg/
mL for each corticosteroid. The between-run accuracy was 4.2% for
prednisolone, 2.8% for cortisol and 3.4% for betamethasone.
3.3. Quantiﬁcation and statistical analysis
Prednisoloneand cortisolweredetected inurine samples fromall
34 individuals. The concentrations, expressed as mean ± SD, of cor-
tisol were 55.13 ± 35.06 and 37.13 ± 39.61 ng/mL, and of predniso-
lone were 440 ± 360 and 470 ± 580 pg/mL, in male and female
urine respectively. The Kolmogorov and Smirnov method showed
normal distributions for cortisol and prednisolone in both male
and female urine. The unpaired t-test, made to compare the urinary
levels between genders, did not show signiﬁcant differences for cor-
tisol (two-tailed P-value = 0.1885) and prednisolone (two-tailed P-
value = 0.8450). Due to this fact, the concentrations of cortisol and
prednisolone in male and female urine were merged. The means
and SD from all the donors were recalculated and the ﬁnal urinary
concentration values were 44.01 ± 38.42 ng/mL for cortisol and
460 ± 500 pg/mL for prednisolone. The concentration ratios of pred-
nisolone/cortisol, calculated for all samples, passed the normality
test and the mean value was 0.01 ± 0.005 with the 95% conﬁdence
limits 0.008 and 0.011. The normality test was made again on
merged data and only cortisol resulted in a normal distribution. Fi-
nally the correlation between cortisol and prednisolone was
checked through the Spearman’s test. A very good positive correla-
tionwas found: the Spearman r valuewas 0.8527with an extremely
signiﬁcant two-tailed P < 0.0001. The non-parametric Spearman
correlation was used because prednisolone did not follow a Gauss-
ian assumption and corresponds to the Pearson correlation for pop-
ulations that follow theGaussian distribution: in general a Pearson r
from 0.7 to 1 is considered to be a strong association [11].
Urine samples of ﬁve out of 34 individuals were collected and
analysed againwithin a six-month interval andprednisolonewas al-
ways detected. The mean ± SD concentrations of urinary predniso-
lone from these ﬁve volunteers only were: 910 ± 390 pg/mL for the
ﬁrst collection and 650 ± 830 pg/mL for the second collection. Corti-
solwas also detected and the corresponding valueswere 90.7 ± 51.6
and 58.6 ± 58.4 ng/mL. A very good positive Spearman correlation
between prednisolone and cortisol levels in both sets of samples
was found as the values were 0.83 and 0.98, respectively.
3.4. Trials on an individual treated with betamethasone
3.4.1. First trial
The urine of the 41-year old male volunteer showed a correla-
tion between prednisolone and cortisol both in the 24-h period
Fig. 2. Circadian rhythm of urinary concentrations of cortisol (dashed line) and prednisolone (continuous line) in a 41-year old male. The arrows indicate the collection time.
Fig. 3. First trial with betamethasone. Suppression of urinary concentrations of cortisol (dashed line) and prednisolone (continuous line) in a 41-year old male during an oral
treatment with 0.5 mg betamethasone, administered once per day for 11 days. The squares on the x-axis represent the administrations; all urine collections were made 12 h
after each administration and 12 and 15 h after the last one.
Fig. 4. Second trial with betamethasone. Suppression of urinary concentrations of cortisol (dashed line) and prednisolone (continuous line), in a 41-year old male during an
oral treatment with 1.0 mg betamethasone (dotted line), administered once per day for 7 days. The squares represent the administrations; all urine collections were made
immediately before, 7 h after each administration, and after different intervals for 3.5 days after the last administration. The values above the arrows represent the time of day
in which the urine collections were made.
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Pearson r in the period before the treatment was 0.97, and the
Spearman r during the treatment was 0.75. In Fig. 2 the daily var-
iation of cortisol and prednisolone urinary concentrations, similar
to the circadian rhythm of plasma cortisol [16], is shown with a
peak at 8.30 A.M. for both cortisol (116 ng/mL) and prednisolone
(1.238 ng/mL). In Fig. 3, the suppression of cortisol and predniso-
lone is shown following the betamethasone administration. Theurinary concentrations of prednisolone and cortisol, measured on
samples collected at 10.00 AM, dramatically decreased after the
ﬁrst treatment, from 543 to 0 pg/ml and from 57.3 to 3.83 ng/mL,
respectively. Prednisolone was not detected during the treatment,
while cortisol slowly decreased to 0 ng/ml at day seven. In the ur-
ine sample collected 15 h after the last betamethasone administra-
tion, prednisolone and cortisol were detected again at the
concentration of 138 pg/mL and 15.1 ng/mL, respectively.
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The same subject underwent a betamethasone treatment in the
subsequent year. The urinary concentrations of cortisol and pred-
nisolone at the moment of the ﬁrst tablet administration
(11.00 P.M.) were 5.92 ng/mL and 97.9 pg/mL, respectively. Beta-
methasone concentrations showed a ﬂuctuation from 11.6 to
32.8 ng/mL during the treatment, and its minimum levels corre-
sponded to the sample collections made at the moment of the oral
administration. The ﬂuctuation was observed for cortisol also, but
the concentrations were inversely proportional: when betametha-
sone raised, cortisol decreased. However, cortisol concentrations
were very low and ranged between 170 and 770 pg/mL. Predniso-
lone was not found eight hours after the ﬁrst betamethasone in-
take and was detected again 2.5 days after the last treatment
(287 pg/mL), together with a peak of cortisol at 10.30 A.M
(26.6 ng/mL), whose concentration was raised from the 37th hour
after the last administration. The circadian rhythm of cortisol and
prednisolone, checked after betamethasone administration, were
also observed in this second trial. In Fig. 4, the urinary concentra-
tions of betamethasone, cortisol and prednisolone detected in this
trial are shown.Fig. 5. Representative full mass LC–MS3 extracted chromatogram depicting the
analysis of a human urine sample. The spectra show the total ion current at the Rt of
the interfering peak (A), prednisolone (B1 and B2) and cortisol (C). In B1 the four
transitions 329? 313; 329? 295; 329? 280 and 329? 187 are considered; in B2
only the m/z 280 and 187.4. Discussion
The LC–MS3 method used in this work considered, for identi-
ﬁcation and quantiﬁcation of prednisolone, the transitions
329? 280 and 329? 187. The reason for this choice is analo-
gous to those already exposed regarding horse urine [13]. A peak
with the same retention time of prednisolone, but a non-
overlapping spectrum was present in the chromatogram. The
m/z 405, the parent ion represented by the formate adduct of
prednisolone ([M + HCOO]), dissociated at 359m/z (i.e. molar
weight of prednisolone minus 1) and 329m/z (i.e. molar weight
of prednisolone minus a CH2OH group). The m/z 359 originated
from the matrix, while the m/z 329 was very abundant and
proved to be an excellent parent ion for the MS3 dissociation.
The transitions 329? 313 and 329? 295 gave rise to possible
misinterpretations, as they were present in another peak, close
to the prednisolone retention time (Fig. 5A and B1). The two
m/z 280 and 187, which were not present in other peaks
(Fig. 5B2), proved to be very characteristic ions in the MS3
method, and were therefore used for identiﬁcation and
quantiﬁcation.
All urine samples showed the presence of both prednisolone
and cortisol and their concentration ratio was about 0.01, with
a narrow range for the 95% conﬁdence limits. This consistency
is the ﬁrst evidence of the endogenous nature of prednisolone,
considered as a by-product or a metabolite of cortisol. Secondly,
it is interesting to note that the same proportion of 1/100 be-
tween prednisolone and cortisol was observed in the collections
of the 24-h study as is shown in Figs. 2 and 4. Thirdly, the inhib-
itory effect of betamethasone concerns both cortisol and prednis-
olone, even if in this last case the 1/100 ratio is not observable
because of the absence of prednisolone in the urine collected
from 24 to 240 h and from 8 to 203.5 h in ﬁrst and second trials,
respectively, and of cortisol from 168 to 216 h in the ﬁrst trial.
These observations reinforce each other, the last two conﬁrming
the ﬁrst one – i.e. prednisolone can have an endogenous origin
in man – as already observed in cow and horse [12,13]. The pos-
sibility of an ex vivo conversion of cortisol to prednisolone [8]
was in advance considered. We therefore eliminated the sample
storage (untreated volunteers) or minimized it (treated individ-
ual). Preliminary trials, performed by placing the urine samples
in the freezer at 18 C for one day, showed no changes in
cortisol and prednisolone levels (personal data, not shown). Acriticism could be made about the fact that the study on the cir-
cadian rhythm linked to the betamethasone-induced suppression
was made on only one volunteer. It has to be noted that this
work was made as a ‘‘natural’’ continuation of the studies made
on bovine and horse and that the availability of a betametha-
sone-treated subject was not provided, but that coincidentally
one of the volunteers had to undergo anti-allergic vernal treat-
ments. Because of our inability to plan the betamethasone treat-
ment, the collection protocols in the two trials are also different.
It seems likely, however, that cortisol and prednisolone take
more than two days to return to the pre-treatment urinary con-
centrations: in the second trial, the circadian rhythm of the cor-
ticosteroids is again evident only at the third day after the
treatment, even if levels are lower than in the ﬁrst trial. It can-
not be excluded, however, that other factors – e.g. different
physiological or stress conditions – could affect the concentra-
tion values as well as the delays in the maximum corticosteroid
levels.
This study is the ﬁrst related to endogenous prednisolone in hu-
mans and, even if further investigations aimed at the demonstra-
tion of the endogenous origin of this corticosteroid could be not
necessary, the deepening of the knowledge about the relationship
that seems to exist between prednisolone and cortisol could be a
reason to continue this work. In particular, the conﬁrmation of
the concentration ratio in pathological and stress conditions, the
study of the metabolic pathways leading to the prednisolone syn-
thesis could represent major topics for the study of a possible role
of this corticosteroid.
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